U.S. Department of CommerceAfter the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance towards the pharmaceutical industry has shifted fundamentally.
Rezon BioRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.
Merus NVDanish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab
Adobe stock photos - Alernon77 Danish Evaxion A/S hat optionally licenced its vaccine EVX-B3.developed with its AI-Immunology™ platform to Merck, Sharp & Dohme. MSD payed UIS$7.5m upfront and offers up to US$592m in milestone payments plus royalties on net sales.
Adobe stock Photos - hkama Overnight, US President Donald Trump broke previous tariff agreements with the United Kingdom and the EU, announcing that from 1 October, patented medicines not produced in the US will be subject to a 100% tariff.
uniqure Amsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for marketing authorisation next year. In addition, UniQure entered into a US$175m non-dilutive senior secured term loan facility with Hercules Capital and commenced a US$200m underwritten public offering of its ordinary shares to prepare a BLA in Q1 2026.
VedaBio IncSiemens Healthineers have participated in a US$25m Series A extension of the CRISPR diagnostics specialist VedaBio Inc and signed a strategic agreement.
Peter de Klerk from Must n Stum/PRNewsfoto/RevyveWageningen-based food-tech scale-up Revyve has raised €24m in a Series B financing, bringing its total capital raised to more than €40 million. The company will use the proceeds to scale up its yeast-based egg replacement to the 1,600 t/a scale.
Roche AGSwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by 2030, Roche Pharma CEO Teresa Graham said at Roche’s Pharma Day in London.
MAES-AREA-EnglosLille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The company will reprioritise its (preclinical) pipeline, including VS-01, which will be further developed in the area of urea cycle disorder (UCD).